protein misfolding therapies (Cambria)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Nameprotein misfolding therapies (Cambria)
Drug Alias Nameprotein misfolding therapies (Cambira)CBM-44282CBM-03350TC-11-202CBM-50381 +[6] 
ClassificationSmall molecules
Mechanisms of ActionNeuroprotectants
TargetsUpdating
Therapy Area/IndicationsAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCambria Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCambria Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsAmyotrophic Lateral Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A